84
Treatment
Start GC 40–60
mg/d and go directly
to Phase II
Continue taper
Phase I
Phase II
Taper GC (to 0
mg at 6 mo with
Tocilizumab)
Target
achieved?
Consult
expert center
Start Tocilizumab
(or Methotrexate)
Risk for or presence of
glucocorticoid-related
adverse events
Taper
tocilizumab or
methotrexate
YES
YES
NO
Figure 25. The 2018 European Alliance of Associations for
Rheumatology (EULAR; Formerly European League
Against Rheumatism) Recommended Algorithms
for the Pharmacological Treatment of Giant Cell
Arteritis
